LLY

(NYSE: LLY)

0.00 unch

MORE ON LLY

DETAILS


Symbol	Value ($)
Previous Close	NA
Open	NA
Day's High	NA
Day's Low	NA
Volume	NA
Avg Daily Vol (13 Wks)	5.09 Mil
Bid	NA
Bid Size	NA
Ask	NA
Ask Size	NA
52-Wk High	NA
52-Wk Low	NA
Dividend Rate	1.96
Yield	NA

Last trade

STOCKSCOUTER

Rating: 8 out of 10
How StockScouter Works

Analyst Rating: Moderate Buy

FINANCIAL HIGHLIGHTS


Symbol	Value ($)
Sales*	22.60 Bil
Income*	4.63 Bil
Sales Growth*	-6.90%
Income Growth*	-6.00%
Net Profit Margin	20.46%
Debt/Equity Ratio	0.30
Beta	0.70
EPS	4.14
Forward P/E	NA
P/E	NA
Market Cap	NA
Shares Outstanding	1.13 Bil

More
* last 12 months

TOP FUNDS HOLDING


NAME	% OWN
Vanguard PrimeCap Fund	2.16%
Vanguard Health Care Fund	1.35%
Vanguard Total Stock Mkt Idx	1.28%

INTRADAY CHART Full-page chart

1D 5D 1M 3M 1Y 3Y 10Y

NEWS

TOP

Eli Lilly Keeps Dividend Steady

Motley Fool | 8 hours ago
Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests

PR Newswire | 11 hours ago
UPDATE 2-Astra, Bristol diabetes drug disappoints in key test

Thomson Reuters | 14 hours ago
The Neuralstem You Don't Know

Seeking Alpha | 14 hours ago
The Diabetes Drug War

Motley Fool | 15 hours ago
Eli Lilly: Cymbalta Antidepressant Sales Forecast

Seeking Alpha | 17 hours ago
UPDATE 3-FDA probes deaths of two patients on Lilly schizophrenia drug

Thomson Reuters | 6/18/2013
Lilly's Zyprexa Under Scrutiny

Wall Street Journal | 6/18/2013
FDA Investigating Lilly’s Zyprexa Injection After Two Die

Bloomberg | 6/18/2013
The FDA Might Pull This Drug From the Market (and Why It Doesn't Matter)

Motley Fool | 6/18/2013

View all news

PRESS REL

Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests

PR Newswire | 11 hours ago
Lilly Declares Third-Quarter 2013 Dividend

PR Newswire | 6/18/2013
New Data Showed LIVALO® (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1c Levels in HIV-infected Adults with Dyslipidemia

PR Newswire | 6/17/2013
Lilly Diabetes, Kris Freeman Kick off Summer with 9th Annual Diabetes Summer Camp Tour

PR Newswire | 6/17/2013
Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease

PR Newswire | 6/13/2013
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

PR Newswire | 6/13/2013
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis

PR Newswire | 6/13/2013
Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly, Novartis and GlaxoSmithKline

PR Newswire | 6/12/2013
Lilly to Highlight Late-Stage Pipeline Molecules at the 73rd American Diabetes Association Scientific Sessions®

PR Newswire | 6/11/2013
Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations on Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association Scientific Sessions®

PR Newswire | 6/11/2013

View all news

COMMENTARY

VIDEO ON MSN MONEY

Feedback

DATA PROVIDERS

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

Page generated 2:17 AM ET

Feedback

RECENT QUOTES

WATCHLIST

You're not signed in

You’re not signed in to MSN Money, so you’re seeing the Watchlist that is tied to your computer. For a more consistent Watchlist experience, sign in to MSN Money. Learn more

View full page

Bing Search

LLY